3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Burkitt Lymphoma
7
Leukemia, Biphenotypic, Acute
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Prostatic Neoplasms
1
Pneumonia
1
Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphohistiocytosis, Hemophagocytic
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hepatectomy
1
Hematologic Neoplasms
1
Drug-Related Side Effects and Adverse Reactions
1
Down Syndrome
1
Brain Neoplasms
1
Blastic Plasmacytoid Dendritic Cell Neoplasm
1
Acute Gout
1
Interventions
Rituximab
41
Cyclophosphamide
36
Prednisone
24
Doxorubicin
23
Magnetic Resonance Spectroscopy
20
Vincristine
19
Lenalidomide
18
Gemcitabine
18
Specimen Handling
17
Biopsy
15
Oxaliplatin
14
polatuzumab vedotin
13
obinutuzumab
11
glofitamab
11
ibrutinib
10
fludarabine
8
Etoposide
8
Dexamethasone
8
CT-P10
8
prednylidene
7
deltacortene
7
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
7
venetoclax
6
tafasitamab
6
pembrolizumab
6
Prednisolone
6
fludarabine phosphate
5
acalabrutinib
5
R-CHOP protocol
5
Cyclosporine
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Large B-Cell, Diffuse
×
Methylprednisolone
×
90 days
×
Clear all
NCT06717347
2026-05-29
MK-2140-010
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,046 enrolled